Monster Beverage $MNST has been quietly building pressure for years, and this quarter may have just been the catalyst it needed.
The company reported mixed results, but the stock still managed to climb 1.4%.
They've now been rewarded for 18 of their last 26 earnings reports.
That’s not noise...
That’s a pattern!
This isn’t some speculative upstart.
It’s one of the most successful stocks of the 21st century. Since 2001, the price has increased by more than 200,000%.
And now, after years of sideways action, it's knocking on the same resistance it’s failed at multiple times before.
Could it be time for the stock to moon again?
So what else did we learn from Friday's earnings reactions? Let’s dive into the details.
Here are the latest earnings reports from the S&P 500 👇
*Click the image to enlarge it
Insulet $PODD had the best reaction score after reporting a double beat.
The company reported revenues of $570M, versus the expected $540M, and earnings per share of $1.02, versus the expected $0.79.
Akamai Technologies $AKAM had the worst reaction score after reporting a double beat.
The company reported revenues of $1.02B, versus the $1.01B estimate, and earnings per share of $1.70, versus the $1.60 estimate.
Now let's dive into the data and talk about what happened with these reports 👇
MNST has been rewarded for 18 of its last 26 earnings reports:
Monster Beverage rallied 1.4% after this earnings report, and here's why:
Consolidated revenues were $90.8B, up 19% year-over-year
Adjusted earnings per diluted share for the quarter were $10.12, a 64% increase from $6.18 a year ago.
The company’s share repurchase program remains active, with $500M (nearly 1% of the current market capitalization) still authorized, providing potential support for the stock.
This company has been one of the best in the Consumer Staples sector for decades. This earnings report further reiterated why that's the case...
Since 2001, the stock has rallied by over 200,000%. This makes it one of the best-performing stocks in the entire market over that timeframe.
After churning sideways for several years, we think the stock is about to resume its long-term uptrend.
If MNST is above 61, the path of least resistance will shift from sideways to higher for the foreseeable future.
MCK has been rewarded for 19 of its last 25 earnings reports:
McKesson rallied 0.5% after this earnings report, and here's why:
Operating expenses rose 22% year-over-year, outpacing revenue growth in some categories.
Gross margin decreased from 82% in Q1 2024 to 80% in Q1 2025.
Prescription Technology Solutions segment revenues increased 13% to $1.3B, with adjusted segment operating profit up 34%.
This company keeps cranking out blockbuster reports after another. We've been so impressed by their management team!
Since bottoming in early 2020, the price has rallied over 500%. This makes McKesson one of the best-performing Health Care stocks during that timeframe.
The stock broke out of a massive base in early 2022 and has soared to 3 key Fibonacci extension levels. We see no reason for this uptrend to end here...
If MCK is above 688, the path of least resistance is likely to remain higher for the foreseeable future.
Thank you for reading.
- The Beat Report Team
PS: While most traders froze during the rotation, Steve got aggressive — and it paid off fast. He just shared every detail of his approach and the new trade ideas that are currently setting up. Watch the replay and get the next one.
If you find our content valuable, we would greatly appreciate it if you could shareit with your friends, family, and colleagues. Your help in spreading the word is invaluable in supporting our work. Thank you to all of you who share!
